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Dendritic cells (DC) represent a heterogeneous population of antigen-presenting cells that
are crucial in initiating and shaping immune responses. Although all DC are capable of
antigen-uptake, processing, and presentation to T cells, DC subtypes differ in their origin,
location, migration patterns, and specialized immunological roles. While in recent years,
there have been rapid advances in understanding DC subset ontogeny, development, and
function in mice, relatively little is known about the heterogeneity and functional specializa-
tion of human DC subsets, especially in tissues. In steady-state, DC progenitors deriving
from the bone marrow give rise to lymphoid organ-resident DC and to migratory tissue
DC that act as tissue sentinels. During inflammation additional DC and monocytes are
recruited to the tissues where they are further activated and promote T helper cell subset
polarization depending on the environment. In the current review, we will give an overview
of the latest developments in human DC research both in steady-state and under inflam-
matory conditions. In this context, we review recent findings on DC subsets, DC-mediated
cross-presentation, monocyte-DC relationships, inflammatory DC development, and DC-
instructed T-cell polarization. Finally, we discuss the potential role of human DC in chronic
inflammatory diseases.
Keywords: dendritic cells, subsets, monocytes, humans, inflammation, inflammatory dendritic cells, functional
specialization, skin
INTRODUCTION
Dendritic cells (DC) have highly effective mechanisms to detect
and capture antigens and to subsequently determine the magni-
tude and quality of adaptive immune responses. They are the most
potent antigen-presenting cells (APC) in promoting activation of
naïve T cells.
In the past years, major advances have been made in under-
standing mouse DC ontogeny, molecular development, and func-
tion. Human DC immunobiology, however, is only beginning to
be understood. Several recent reviews have aligned data on human
and mouse DC networks (1, 2) and have highlighted similarities,
parallels, and differences. In the current review, we will put the
human DC subsets in the spotlight and focus on recent advances
in human DC development and functional specialization, both in
steady-state and in inflammatory conditions.
HUMAN DC SUBSETS
Dendritic cells are heterogeneous and can be sub-classified based
on anatomical location, origin, and function. After exiting the
bone marrow into the blood, DC progenitors give rise to res-
ident and migratory DC following final in situ differentiation.
Resident DC are localized in lymphoid tissue (LT) where they
take up antigen from the lymph and bloodstream and present
it to local T cells. Non-lymphoid tissue (NLT) DC constitutively
migrate from the tissues to the lymph nodes where they present
tissue-derived antigens to T cells. In peripheral blood, three main
DC subsets have been acknowledged within the HLA-DR+ lin-
eage negative fraction that can be identified based on their surface
marker expression: plasmacytoid DC (pDC) and two types of con-
ventional DC (cDC); CD1c/BDCA-1+ cDC, and CD141/BDCA-
3+ cDC (3, 4) (Figure 1). These subsets can also be found in
spleen and tonsils (5–7). Hierarchical clustering of mouse LN and
human blood DC subsets based on genome-wide expression pro-
filing demonstrated clustering of human pDC with mouse pDC,
CD141+ cDC with mouse CD8α+ DC, and human CD1c+ cDC
with mouse CD11b+ DC (8). The total blood DC population con-
sists of about 5–10% CD141+ cDC while the remainder is divided
into equal parts pDC and CD1c+ cDC (9).
Segura and colleagues recently demonstrated that resident
LN DC subtypes also phenotypically correspond to blood pDC,
CD1c+, and CD141+ cDC (10). Whereas cDC are thought to reach
the LN after trafficking from peripheral tissue via afferent lym-
phatic vessels, pDC have been described to migrate directly from
the blood to the LN via high endothelial venules (HEV) (11).
In general, NLT DC have a more activated phenotype express-
ing higher levels of co-stimulatory molecules than their blood
counterparts. In the skin, lung, and liver two cDC subsets identi-
cal to CD1c+ and CD141+ blood cDC have been identified (12,
13), whereas pDC are absent in tissues under steady-state condi-
tions. Human CD1c+ and CD141+ tissue-resident DC are related
to mouse tissue-resident CD11b+ and CD103+ DC, respectively
(12). In addition to cDC, human tissues also harbor migratory
CD14+ DC, which are not found in the blood (12, 13) and do not
have an identified murine equivalent. However, CD14+ NLT DC
display an intermediate phenotype expressing both macrophage
and DC markers, and the transcriptomic expression profiles of
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FIGURE 1 | Monocyte and dendritic cell populations in human
peripheral blood during steady-state conditions. Expression of markers
commonly used to identify and discern these populations are indicated.
Additionally, frequencies (%) of monocyte subsets within the monocyte
pool and dendritic cells within the dendritic cell pool are specified.
skin and lung CD14+ DC recently were demonstrated to be most
closely related to blood monocytes and tissue macrophages (12,
13), which questions their DC origin.
DC DEVELOPMENT
In mice, the macrophage and DC progenitor (MDP) gives rise
to monocytes and the common DC progenitor (CDP). The lat-
ter has lost the potential to generate monocytes and macrophages
[reviewed by Ref. (14, 15)]. Recent fate-mapping and cellular bar-
coding studies have confirmed cDC as an independent hematopoi-
etic lineage (16, 17). In the bone marrow, CDP give rise to pre-DC
that migrate via the blood into LN and NLT, and terminally dif-
ferentiate into LN and NLT cDC subsets. Once in the periphery,
DC have a short life-span and retain a high degree of plastic-
ity that enables a rapid and diverse response to specific extrinsic
stimuli.
Human DC arise from BM precursors and it has recently been
shown that both granulocyte-macrophage progenitors (GMP) and
multi-lymphoid progenitors (MLP) can generate DC in vitro or
following adoptive transfer experiments in mice (18). Consistent
with this, in vivo data on human DC deficiency caused by a GATA2
mutation demonstrate that a complete absence of MLP (and only
reduced numbers of GMP) results in loss of all DC (19). It is
unknown however, whether committed DC progenitors exist in
humans. So far, equivalents of mouse MDP, CDP, and pre-DC have
not been found. Identification of early DC precursors in human
blood is complicated by the fact that, in contrast to mouse DC pre-
cursors, human CD34+ hematopoietic stem cells already express
MHC class II. It has been speculated that human circulating cDC
may be regarded as pre-DC that undergo their final DC differenti-
ation stage in situ (4, 10, 13). CD1c+ and CD141+ cDC proliferate
more in the blood than in the LN (10, 20), suggesting that in the
blood they are not fully differentiated. In contrast to cDC, both
blood and LN-derived pDC do not proliferate (10, 20), supporting
the idea that pDC leave the bone marrow fully differentiated (21).
HUMANMONONUCLEAR PHAGOCYTE SYSTEM: HOW DC
DIFFER FROMMONOCYTES AND MACROPHAGES
The human mononuclear phagocyte system has historically been
divided into macrophages, monocytes, and DC, with classification
mainly based on phenotypic, anatomical, and/or functional cri-
teria. In this classification, DC are distinguished from monocytes
and macrophages amongst others by their dendrite morphology,
high levels of MHC class II expression, and superior migra-
tory and naïve T-cell priming properties. Transcriptional profil-
ing studies have confirmed that quiescent primary CD1c+ cDC,
CD141+ cDC, and pDC cluster together and form distinct popu-
lations separate from monocytes and macrophages (8). However,
recent studies have also revealed cases of “mistaken identity” and
have challenged several long-standing paradigms regarding the
ontogeny and (functional) classification of APC. Especially during
inflammation or infection, classifying APC subsets is complicated.
MONOCYTES
Monocytes are the most prominent mononuclear phagocyte of
the blood compartment and display a wide array of scavenger
and pattern recognition receptors that enables them to rapidly
respond to danger signals and pathogen encounter. The classical
view is that monocytes circulate in the blood for a few days before
migrating into tissues where they can develop into macrophages
or DC. Renewed interest in recent years has revealed that mono-
cytes may not just be simple transitional and reactive cells but, like
DC, display functional diversity and play a critical role in pathogen
defense and driving inflammatory diseases.
Human blood monocytes can be distinguished from DC by
the expression of CD14, although surface expression levels can
vary. It is important to note that while CD11c is a specific DC
marker in mice,>95% of human monocytes also express CD11c.
Three different types of monocytes have been described based
on the expression of CD14 and CD16 (FcγRIII) and classified by
expression profiling and hierarchical clustering (4, 22): (1) clas-
sical CD14++CD16−, (2) intermediate CD14++CD16+, and (3)
non-classical CD14+CD16++ monocytes (Figure 1). A dispar-
ity with DC subsets is that monocyte subsets seem to merely
represent subsequent developmental stages; although there is
no real evidence it is believed that monocytes leave the bone
marrow as CD14++CD16− and can develop via intermediate
CD14++CD16+ into non-classical CD14+CD16++ monocytes
(22). Classical CD14++CD16− monocytes are most prevalent in
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the blood (about 85% of all monocytes) and are rapidly recruited
to tissues in inflammatory responses. CD16-expressing monocytes
in general display an advanced stage of differentiation with DC and
macrophage-like characteristics and effector functions related to
antigen processing and presentation. Numbers of blood CD16+
monocytes rise in inflammatory conditions and they represent
the main producers of inflammatory cytokines such as TNFα.
Especially, the intermediate subtype appears to be highly pro-
inflammatory and has the highest capacity to stimulate (antigen-
independent) T-cell responses (22, 23). The CD14dimCD16++
intermediate monocytes can be further subdivided into 6-sulfo
LacNAc-positive (slan) and -negative monocytes that both pro-
duce high levels of IL-12, TNFα, and IL-1β. The expression of slan
was initially identified on an inflammatory human DC subset, the
so-called slan DC (24). These cells were found both in blood and
skin tissue (24, 25). However, recent data show that slan DC clus-
ter together with, and are indistinguishable from, blood CD16+
monocytes (13, 23). This example reveals the difficulties in cate-
gorizing APC subsets and even lineages based on surface marker
expression and functional characteristics. As will also be discussed
further on, CD14+ NLT APC, originally classified as DC, may
actually represent classical monocytes that have extravasated dur-
ing steady-state. In line with this, it has been recently challenged
whether monocytes become tissue macrophages or DC by default
when they exit the bloodstream. Jakubzick and colleagues demon-
strated that in steady-state, murine classical monocytes extravasate
continuously and carry tissue-derived antigens to the LN without
differentiating into macrophages or DC (26). Although monocytes
express high levels of MHC class II and also have been shown to
be able to retain captured antigen and present antigen-derived
peptides, they are relatively poor antigen presenters (21, 23).
Alternative mechanisms such as cytokine production or antigen
sharing with DC may however contribute to supporting adaptive
immunity.
Together, recent data point to a model in which under homeo-
static conditions monocytes may not represent “simple” convert-
ing cells but play a specific and complementary role to DC in tissue
surveillance and promoting adaptive immunity. For full differen-
tiation into tissue macrophages or DC, additional triggers may be
required. As will be discussed further on (functional) relationships
between monocytes and DC/macrophages are completely different
during inflammation.
MACROPHAGES
Macrophages consist of two types: tissue-resident and infiltrat-
ing macrophages. Tissue-resident macrophages are, as opposed to
DC and monocytes, long-lived non-migratory cells that are spe-
cialized in taking up and processing dead cells and debris. They
possess high proteolytic activity and are poor antigen presenters.
They play an essential role in maintaining tissue homeostasis by
clearing cell debris and promote resolution of inflammation and
wound healing (27). However, they can also promote inflamma-
tion by the production of chemokines like CCL2, CXCL1, and MIF,
and cytokines like IL-6 and TNFα, attracting and activating other
immune cells (28, 29).
Tissue macrophages are highly heterogeneous, a consequence
of their tissue-specific niches, but functional specialization in situ
is difficult to establish. The origin of tissue-resident macrophages
has long been controversial: are they monocyte-derived or self-
maintaining? Recent studies in mice show that under steady-state
conditions most tissue macrophages are present from birth and
are self-maintaining, independently from monocytes (30–33). As
an exception, intestinal macrophages have been shown to be
constantly replaced by blood monocytes that in healthy tissue
conditions acquire a regulatory expression profile (34). Consis-
tent with the findings of independency from monocytes in mice,
several human primary immune deficiencies are associated with
severe monocytopenia (35–37) and loss of circulating and tis-
sue DC (35, 36) while tissue macrophages are relatively unaf-
fected. Whether tissue macrophages in humans are completely self-
renewing remains to be established since tissue macrophages do
not appear to proliferate in situ in steady-state (38) and older data
also show involvement of BM-derived cells in the replenishment
of tissue macrophages following stem cell transplantation (39).
The second type of macrophages, the infiltrating macrophages,
is recruited to tissues in inflammatory conditions. In mice, inflam-
matory monocytes, resembling human classical monocytes and
identified by the expression of Ly6c/GR1 and CCR2, have been
found to be the source of infiltrating macrophages; distinction
between these and resident macrophages can be based on Ly6c
expression since Ly6c expression was mostly stable during the first
24 h after infiltration while resident macrophages were negative
for this marker (29, 40, 41). In the human setting however, there is
still no marker to distinguish infiltrating macrophages from resi-
dent macrophages, which makes it hard to study subpopulations.
Infiltrating macrophages can be divided into three main popula-
tions, with a spectrum of macrophage subpopulations in between,
based on function, displaying either a pro-inflammatory profile
(originally coined “classically activated” or “M1” macrophages),
a regulatory profile, or a wound-healing profile (both origi-
nally grouped under the term “alternatively activated” or “M2”
macrophages) depending on the tissue context and environmental
stimuli (42, 43).
FUNCTIONAL SPECIALIZATION HUMAN DC: STEADY-STATE
Due to technical reasons, DC research in humans is largely
restricted to peripheral blood-derived DC, using either ex vivo pri-
mary DC or in vitro monocyte-derived DC (Mo-DC). A unique
and key feature of DC is their ability to prime naïve T cells. Both
cDC subsets, and to a lesser extent pDC, have been shown to prime
CD4+ T cells, this in contrast to freshly isolated blood monocytes.
For efficient in vitro CD8+ T-cell priming all DC subsets require
either TLR stimulation or CD4+ T-cell help (20).
PLASMACYTOID DC
Plasmacytoid refers to the non-dendritic, plasma cell-like mor-
phology of pDC in their inactivated state. pDC are characterized by
the expression of CD123 (IL-3R), CD303 (BDCA-2), and CD304
(BDCA-4 or Neuropilin-1) and circulate in the blood and LN com-
partments. Their most notable feature is their ability to quickly
secrete large amounts of Type I interferons (IFN) in response to a
viral infection (44). pDC selectively express endosomal TLR7 and
TLR9 that detect nucleic acids derived from viruses, bacteria, and
dead cells. TLR7 or TLR9 ligation triggers a downstream signaling
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cascade resulting in secretion of IFN-α, IFN-β [reviewed by Ref.
(45)], and IFN-λ (46, 47).
In steady-state, pDC have a poor capacity to stimulate CD4+
T cells due to their low levels of MHC class II and co-stimulatory
receptor expression and limited phagocytosis of antigens. With-
out stimulation pDC seem to be tolerogenic and are implicated
in inducing T-cell anergy and promoting regulatory T-cell devel-
opment (48, 49). Following stimulation, pDC acquire a dendritic
morphology, upregulate HLA-DR and co-stimulatory molecules,
and differentiate into functional APC capable of naïve CD4+ T-cell
activation (45).
CONVENTIONAL DC
Both CD1c+ and CD141+ cDC are found in the blood, LN, spleen,
and NLT including skin, liver, lung, and gut. CD1c+ cDC co-
express CD11b and high levels of CD11c whereas CD141+ DC
express lower levels of CD11c, lack CD11b, and selectively express
CLEC9A (13, 50, 51). The chemokine receptor XCR1 was found
to be the most selective marker for both human CD141+ DC
and mouse CD8α+ DC when compared to other DC subsets and
monocytes (52, 53). Additionally, the ligand for XCRI, XCL1, selec-
tively attracts CD141+ DC and mouse CD8α DC in vitro (52, 53)
and was shown to be required for optimal in vivo priming of CD8
T cells in mice (52).
The two cDC subtypes differ in TLR expression pattern and
responsiveness. Whereas CD1c+ cDC express all TLR except TLR9,
CD141+ cDC highly express TLR3 and TLR10, have low expres-
sion levels of TLR1-2, TLR6, and TLR8, while they lack TLR4-7
and TLR9 (51, 54). Stimulation of sorted cDC subsets with TLR
ligands confirmed restrictive responsiveness of CD141+ cDC and
showed differential cytokine/chemokine profiles. CD141+ cDC
were found to predominantly respond to TLR3 ligand (poly I:C)
triggering by producing CXCL-10/IP-10, CCL5, and IFN-β. Poly
I:C also induced the selective production of IFN-λ, a type III
IFN with anti-viral properties (51, 54, 55). Skin-derived CD141+
were shown to secrete high amounts of CXCL-10 and TNFα upon
TLR3 triggering (13). CD1c+ cDC display a broader repertoire of
secreted proteins including IL-1β, IL-12, IL-6, TNFα, CXCL8/IL-
8, CCL3, CCL4, and CCL5 and CXCL-10 upon TLR3 stimulation
(51, 54). Selective high production of IL-12 by CD1c+ DC was
confirmed upon stimulation with a combination of TLR ligands
(20), although use of a different cocktail, of poly I:C plus cytokines,
showed that CD141+ DC, too, are well able to produce IL-12p70
(51). Most likely available environmental stimuli will determine
local production of this and other cytokines by specific cell subsets.
ANTIGEN PRESENTATION
Primary CD1c+ and CD141+ have a similar capacity to take up
fluorescent protein and they were shown to process and present
recombinant protein to autologous CD4+ T cells with similar
efficiency (51). In addition, they express similar levels of MHC
class I and are equally efficient in peptide antigen presentation
to autologous CD8+ T cells (51). Antigen processing and presen-
tation requires limited degradation of proteins and preservation
of cognate T-cell epitopes. Similar to mouse DC, ex vivo human
pDC and cDC have been shown to contain low proteolytic activity
(56). In contrast, Mo-DC show high protein degradation capacity,
comparable to that of macrophages (56). With maturation, lyso-
somal pH drops and degradation capacity increases, which may
explain the increased degradation of proteins found in Mo-DC.
T-CELL POLARIZATION
Antigen-presenting cells and their secreted products are believed to
be decisive in naïve T-cell differentiation and CD4+ TH-cell subset
polarization. Accordingly, CD4+ T-cell differentiation was found
to be defective in a patient with IRF8 autosomal recessive defi-
ciency, characterized by the lack of monocytes and DC. Whereas
ex vivo CD4+ T-cell proliferation was within normal range, pro-
duction of IFN-γ, IL-17, and to a lesser extent IL-10, was largely
reduced in response to CD3/CD28 or PMA/ionomycin (36).
In an allogeneic MLR both cDC subsets are equally strong
stimulators of CD4+ T cells regardless of their activation sta-
tus (51), however T-cell polarization capacities may differ based
on the differential TLR and cytokine/chemokine expression pro-
files. High expression of TLR3 by CD141+ DC and their capacity
to produce high amounts of IFN-β, CXCL-10, and IL-12p70 all
point to TH1-inducing function. Indeed, unstimulated CD141+
and CD1c+ cDC were found to induce TH1 differentiation from
naïve CD4 T cells, with TLR stimulation further promoting this
capacity (51, 54). The highest percentage of IFN-γ-producing cells
was observed following TLR3 triggering of CD141+ cDC (54).
Both unstimulated and poly I:C-stimulated cDC subsets did not
induce IL-4, IL-5, and IL-10 production in an allogeneic MLR (51)
and, in general, blood DC fail to induce efficient TH2 polariza-
tion (10). In contrast, LN-resident cDC subsets induce both TH1
and TH2 cytokine production in naive allogeneic T lymphocytes
(10) and skin resident Langerhans cells (LC) have been shown to
preferentially induce differentiation of TH2 cells (57).
Schlitzer and colleagues have assessed TH17 induction by
human DC subsets from peripheral blood and lung tissue. Unstim-
ulated lung CD1c+ DC were found to express levels of IL-23p19
mRNA higher than those expressed by CD141+ DC but compara-
ble to those expressed by CD14+ DC/monocytes (12). Consistent
with this, both lung and blood CD1c+ DC more potently induced
IL-17 production by autologous CD4+ T cells than CD141+ DC
and CD14+DC/monocytes. Unstimulated CD141+ from the liver
were however reported to induce both IL-17 and IFN-γproduction
by allogeneic T cells (58).
CROSS-PRESENTATION
Cross-presentation is the presentation of acquired exogenous anti-
gens on MHC class I molecules and is essential for the initia-
tion of CD8+ T-cell responses (59, 60). In mice, steady-state LN
CD8α DC seem to be the most efficient at cross-presentation
(60–62). When CD141+ cDC were identified as mouse CD8α+
homologs (8) numerous groups subsequently described superior
cross-presenting ability of blood CD141+ cDC (50–53). Whereas
one study showed superior cross-presentation of unstimulated
CD141+ cDC compared to CD1c+ cDC and pDC (53), other
groups reported that unstimulated CD141+ cDC were unable to
cross-present (6, 20, 51). Recent studies have revealed that, with
the proper stimuli, all human DC subsets are able to cross-present
in vitro (63). However, CD141+ cDC were shown to be the most
efficient cross-presenting subset following poly I:C stimulation
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(20, 51, 52), when using necrotic cell-associated antigens (51,
53), antigen delivered by Fcγ receptor targeting (64), or anti-
gen delivered to late endosomes/lysosomes (65). The superior
ability in cross-presenting necrotic cell-derived antigens may be
explained by the selective expression of Clec9A on CD141+ cDC
(as well as on CD8α+ mouse DC), a dead cell receptor that favors
cross-presentation through cargo delivery to both MHC class I
and II (51).
In vivo cross-presentation occurs in secondary lymphoid
organs and the Amigorena group has demonstrated that freshly
isolated tonsil-resident LN CD1c+ cDC, CD141+ cDC, and pDC
all display equal intrinsic cross-presenting capacity (66). In addi-
tion, ex vivo unstimulated skin-derived LC and CD141+ cells
potently cross-present (13, 57). It has therefore been suggested that
blood DC may not be fully functional yet and only acquire efficient
cross-presenting capabilities after a final step of differentiation in
lymphoid organs and tissues (66).
Taken together these data demonstrate that although CD141+
have characteristics of specialized cross-presenters compared to
other DC subsets, this is highly affected by activation status, loca-
tion, type of antigen, and inflammatory signals (63). It is also
important to note that the requirements for DC subsets to effi-
ciently cross-present may be different than those to stimulate
CD8+memory T cells/T-cell clones versus priming of naïve CD8+
T cells.
FUNCTIONAL SPECIALIZATION HUMAN DC: INFLAMMATION
In an inflammatory setting, monocytes/DC change their pheno-
type thereby complicating the distinction between phenotypic
plasticity within a monocyte/DC population versus discrete sub-
sets. For example, APC can upregulate phenotypic “markers” such
as CD14, CD11b, CD141, and CD16, which are used in steady-
state to define lineages or functional subsets. Another compli-
cating factor is tissue-instructed differentiation, which confounds
hierarchical clustering and principle component analyses. When
CD1c and CD141 peripheral blood and tonsilar tissue DC were
used for transcriptional profiling and hierarchical clustering, tran-
scriptional activity was more pronounced in tonsil DC and with
more transcriptional overlap between the subsets compared to the
blood-derived counterparts (7). It was suggested that this is most
likely the effect of inflammatory maturation stimuli present in the
tonsilar tissue (7) and in general most tissue-specific effects may
be due to the induction of different states of maturation. Both
mouse and human DC have indeed been shown to undergo pro-
found genetic reprograming in vivo during their maturation (67).
Interestingly, genes that were identified to be regulated upon DC
maturation were irrespective of stimuli, species, or DC subsets. In
addition, following an in vivo virus challenge mouse DC subsets
underwent similar extensive reprograming in their gene expres-
sion pattern but maintained their own subset profile, suggesting
a common and conserved maturation program without loss of
identity (67).
Along with phenotypical changes, functional changes occur
following maturation. In general, microbial encounter or inflam-
matory stimuli change the main function of DC from phagocy-
tosis into efficient priming of T cells. After a transient increase
in antigen-uptake, changes in endosomal trafficking and antigen
processing lead to increased presentation and, along with upreg-
ulation of co-stimulatory molecules, this results in efficient T-cell
stimulation. One example of a functional change is the observa-
tion that all blood DC can cross-present after stimulation with
TLR agonist, while in steady-state the capacity to cross-present is
limited (10, 51, 52).
INFLAMMATORY DENDRITIC CELLS: THE RELATIONSHIP BETWEEN
MONOCYTES AND DENDRITIC CELLS IN INFLAMMATORY CONDITIONS
One of the important outstanding questions in DC biology is the
(functional) relationship between DC and monocytes in inflam-
matory conditions. Monocytes have long been known to be able to
differentiate into DC when properly stimulated in vitro (68, 69).
The best-studied human DC are in fact in vitro-generated Mo-DC
since they can be generated in large numbers (69). Genome-
wide expression profiling has demonstrated that human GM-CSF
Mo-DC have more similarities with monocytes than with blood
DC subsets (8). Therefore, GM-CSF Mo-DC may share a num-
ber of developmental, phenotypic, and functional characteristics
with so-called “inflammatory” DC (infDC) – DC derived from
monocytes in an inflammatory setting. However, in humans it
has never been demonstrated that monocytes give rise to DC
in situ. In mice, the in vivo role of Mo-DC have also long been
elusive until in 2003, two studies showed in vivo differentiation of
monocytes into the above mentioned infDC (70, 71). These infDC
were shown to be recruited to the site of inflammation, produc-
ing large amounts of TNFα and iNOS (therefore, they were also
referred to as TNF–iNOS producing “Tip” DC) and were found to
be crucial in pathogen clearance (71). Later, it was demonstrated
that infDC are also essential in promoting early pathogen-specific
T-cell responses (72), although it has not yet been formally demon-
strated whether they are involved in in vivo T-cell priming. infDC
seem to be specifically important in stimulating T-cell polarization
and cytokine production (73). In mice, infDC preferentially induce
TH1-type responses, but TH2 or TH17 type responses have also
been reported [reviewed by Ref. (73, 74)] depending on the type of
(inflammatory) environment. Taken together, monocyte-derived
infDC play an important role in the initiation of inflammation and
with their rapid and numerous recruitment to inflamed/infected
sites and high production of inflammatory cytokines they may act
as safeguards that support the function of cDC. Additionally, their
highly plastic and versatile nature enables them to respond to local
cues and acquire specific activities.
Identifying the in vivo human counterpart of infDC has proven
to be a challenge. As discussed further on, several infDC phe-
notypes have been described that are present only in inflamed
skin, including Tip-DC and inflammatory dendritic epidermal
cells (IDEC). Although all these DC subsets can be considered
infDC, their origins and mutual relationship are currently unclear.
In the duodenal mucosa of celiac disease patients, there is a
rapid accumulation following a gluten challenge of inflammatory
CD11c+CD14+CD163+CCR2+ DC, which are suggested to be
monocyte-derived due to their phenotypic overlap with classical
blood monocytes (75). In the lungs of mice, upon inflammatory
conditions like respiratory viral infections, an influx of activated
inflammatory CD11b and Ly6c-expressing DC is found, together
with IFN-producing killer DC that are CD11cdim and B220+ [as
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reviewed in Ref. (76)]. These lung-infiltrating CD11b+ Mo-DC
were shown to be important in the production of chemokines dur-
ing allergic inflammation and were capable of inducing TH2 cell
immunity (74). Additionally, in viral-induced pulmonary inflam-
mation, CD11b+ Mo-DC induce strong naïve T-cell proliferation
and produce NO synthase 2 (NOS2), playing a predominant role
in pathology (77). However, again, how this translates to the
human setting remains to be investigated. Another very recent
paper describes a specific subset of DC, present in synovial fluid
(SF) of RA patients and in inflammatory tumor ascites, that shares
molecular features with both conventional CD1c+ DC and mono-
cytes/macrophages (78). These CD1c+ infDC co-express CD14,
CD206, and CD11b, and are enriched for a Mo-DC signature.
Although these data indicate a close relationship with monocytes,
also here it remains to be established whether they are derived
from monocytes or merely represent activated CD1c+ DC. In
terms of function, CD1c+ exudate-derived infDC were demon-
strated to promote IFN-γ and IL-17A production by autologous
memory T cells and induce IL-17A production by naïve allogeneic
T cells and (78) by the production of TGF-β, IL-1β, IL-6, and IL-
23, stressing their pro-inflammatory nature. Although exudates
are only a partial reflection of what is going on in the inflamed
tissues, the highly inflammatory environment and presence of
large cell numbers provide an excellent tool to study APC biol-
ogy and interaction with activated T cells under inflammatory
conditions. We have demonstrated that in SF of juvenile idio-
pathic arthritis patients T cells become resistant to Treg-mediated
suppression and that impaired T-cell regulation can be specifically
induced by the APC-derived pro-inflammatory cytokines IL-6 and
TNFα (79, 80).
HUMAN DC IN CHRONIC AUTOIMMUNE INFLAMMATION
Substantial support is available for the pathogenic role of DC in
multiple autoimmune diseases by driving activation and differen-
tiation of effector T-cell populations (81). However, the specific
functional roles of DC subsets, as opposed to the general popu-
lation of DC remains to be established and is one of the future
key questions. The best example of the involvement of a specific
DC subset in human autoimmune disease so far is the pDC driven
type I IFN pathogenesis proposed in several systemic autoimmune
diseases. Whereas pDC are largely absent from tissues in steady-
state they can accumulate during inflammation. As pDC are not
only able to sense viral nucleic acids but also self-nucleic acids in
injured tissue leading to their activation and type I IFN produc-
tion. Tissue infiltration of activated pDC has been reported in skin
lesions of SLE, psoriasis, and systemic sclerosis patients (82, 83),
salivary glands of Sjögren’s disease patients (84), and muscles and
skin of juvenile dermatomyositis patients (85). In these autoim-
mune diseases, pDC are the major source of type I IFN and are
implicated in the initiation of inflammation and the transition to
a chronic disease (81).
Migratory tissue DC play a central role in the induction of
inflammation. Due to relatively easy accessibility, most human
tissue DC work has been performed on skin tissue-derived DC.
Therefore, in the next part we will discuss in more detail the func-
tion of DC subsets in healthy and (chronically) inflamed skin as a
model for human tissue DC biology.
SKIN DC: STEADY-STATE
The skin hosts several distinct DC subsets within its two compart-
ments and the classical categorization consists of LC, residing in
the epidermis, and CD1a+CD14− and CD14+ DC, residing in the
dermis (86, 87) (for an overview of skin DC in steady-state see
Figure 2).
LANGERHANS CELLS
Langerhans cells, due to their location in the epidermis and their
protruding dendrites, are a typical example of a DC sentinel, sur-
veying the epidermis for foreign antigens. With their continuous
migration to draining LN, they constitute the first immunolog-
ical barrier of the skin. In human, LC can be identified based
on the expression of CD11c, CD32, CD45, FcεR1, high levels of
CD1a, CD207/langerin, CD324/E-cadherin, CD326/EpCAM, and
HLA-DR, and specific expression of Birbeck granules (88, 89). In
steady-state, LC are continuously replaced from a resident pre-
cursor pool (90), whereas in inflammation LC are repopulated by
blood precursors (91).
In vitro human LC are able to take up antigens, process them
efficiently and present them to T cells to induce activation, prolifer-
ation, and cytokine production (57). They are able to initiate TH1,
TH2, TH17, and TH22 responses (92). LC migrate to skin-draining
lymph nodes in steady-state (10, 93), and LN-derived LC have
been found to preferentially induce TH2 polarization in vitro (10).
Additionally, LC are rather efficient at cross-presenting exogenous
antigen to naïve CD8+ T cells (57, 94).
DERMAL DC
In human dermis, during steady-state conditions, DC are classi-
cally divided into CD14+ and CD1a+ DC (86). CD14+ dermal
dendritic cells (DDC) show variable expression of CD1a, CD1c,
and CD163 (38). Dermal resident macrophages also express CD14
but they can be distinguished from DDC by the lack of CD1c
and the presence of high levels of CD163 and FXIIIa and high
auto-fluorescence (38, 95). Nevertheless, CD14+ DDC express a
FIGURE 2 | Dendritic cell populations in human skin during
steady-state conditions. Expression levels of markers commonly used to
identify and discern these populations are indicated.
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prominent “mixed” DC/macrophage phenotype and comparative
transcriptomic analysis has recently demonstrated the close rela-
tion of CD14+ DDC with blood monocytes (13, 96), suggesting
a monocyte origin. These cells should not be confused with Mo-
DC or infDC that only appear during inflammation and display
an activated and pro-inflammatory phenotype. CD14+ DDC in
contrast express low levels of CD80 and CD86 and are relatively
poor inducers of naïve T-cell proliferation (38, 57, 95, 97, 98). They
do however efficiently take up antigen, possibly due to expression
of c-type lectins like CD206 and CD209/DC-SIGN (95, 99). They
also have the ability to induce Treg through high production of
IL-10 (100).
Skin-derived CD1a+DC express high levels of CD80 and CD86
and strongly induce allogeneic naïve CD4+ T cells and CD8+ T-
cell proliferation (38, 57, 95, 97, 98). CD1a+ DDC isolated from
skin-draining lymph nodes were found to preferentially induce
TH2 polarization similar to LC (10). However, human CD1a+
DDC seem to be more heterogeneous than originally thought.
The majority of CD1a+DDC are uniformly CD1chigh, but recently
CD1clo DDC highly positive for CD141 were isolated from skin
explants. These DC resembled the phenotype of blood CD141+
DC, expressing high levels of XCR1, TLR3, CLEC9A, CADM1,
and FLT3, and were found to be superior to CD1c+ DDC, CD14+
DDC, and LC at cross-presenting soluble antigen (13). In contrast
to blood CD141+ DC cross-presentation by CD141+ DDC was
even induced in the absence of TLR3 stimulation, which under-
scores their activated phenotype. Variable expression of CD141 on
CD14+DDC has also been reported (13, 100). However, these cells
lack the critical features of cross-presenting DC (13) and induce
Treg via the production of IL-10 (100).
SKIN DC: INFLAMMATION
Inflammatory diseases of the skin have been associated with altered
DC numbers, suggesting a role of DC in these pathologies. How-
ever, what role DC play is often still unclear and remains to
be resolved. In both atopic dermatitis (AD) and psoriasis, the
two most common inflammatory skin diseases, DC numbers are
increased (for an overview see Figure 3). To elucidate the role that
DC can play in skin inflammation and inflammation in general,
FIGURE 3 | Dendritic cell populations in human skin during inflammatory
conditions. Inflamed skin contains not only DC that were already present at
steady-state (A), but also DC that migrated into the skin (B). Markers
commonly used to identify these DC populations are indicated, as well as
markers/function associated with specific inflammatory conditions of the
skin. LC, Langerhans cell; Ps, psoriasis; AD, atopic dermatitis.
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we will draw examples from psoriasis and AD, each with their own
TH-cell signatures.
PSORIASIS
Psoriasis is a common relapsing immune-mediated inflammatory
disease affecting skin and joints, typically presenting as well-
demarcated, red, and scaly plaques (101). The typical histological
features of psoriatic plaques like thickening of the skin, elongation
of the epidermis, and increased numbers and dilated dermal blood
vessels, are caused by an immune response gone out of control, in
which keratinocytes, DC, and T cells all play a role. In psoriatic
lesions, CD8+ T cells are mostly found in the epidermis, while
pDC, myeloid DDC and TH1 and TH17 CD4+ cells, are found in
the dermis (102).
Plasmacytoid DC
In psoriatic lesions, the type I IFN system has been shown to
be activated when compared to non-involved skin of the same
patient or healthy control (HC) skin (103). Activated pDC are
found in increased numbers not only in lesional psoriatic skin
(104, 105), but also in uninvolved skin of psoriatic patients, com-
pared to normal skin from HC (104). IFN-α signaling, but not
IFN-α expression, is upregulated only in lesional psoriatic skin.
Following exposure to light, a well-established treatment for pso-
riasis, pDC numbers and IFN-α signaling are rapidly reduced in
lesional skin, in parallel with a clinical improvement (106). The
underlying mechanism of pDC activation in psoriatic skin seems
to be via the cathelicidin LL37, an antimicrobial peptide that is
produced by keratinocytes and neutrophils and is overexpressed in
psoriatic skin. This peptide binds self-DNA/RNA fragments that
are released from stressed or dying skin cells, and subsequently
triggers TLR7/9 on pDC to induce activation and production of
type I IFN (107, 108). Similarly, other proteins secreted by neu-
trophils via the neutrophil extracellular trap (NET) like HMGB,
HNE, CatG, and SLP1, together with DNA induce pDC to pro-
duce IFN-α, and possibly play a role in early psoriasis (109–111).
Indeed, in a case report, triggering of TLR7 via topical treatment
with TLR7 ligand imiquimod was shown to induce exacerbation of
psoriasis via massive induction of type I IFN signaling (112). Sim-
ilarly, in some skin-related cancers, in which imiquimod is used as
a topical therapy, imiquimod application strongly increased IFN-α
signaling that was related to the number of pDC, suggesting that
again pDC-derived IFN-α is responsible for this (113).
While in early and developing psoriasis the role of pDC seems
clear, a role in more chronic psoriasis is less distinct. Indeed, when
corresponding pDC to phases of psoriasis, pDC are especially
found in early and developing psoriasis, and hardly in chronic
psoriasis. This temporal dichotomy correlates well with chemerin
levels, a chemokine that attracts chemR23-expressing pDC and is
highly expressed in pre-psoriatic skin and early lesions (114, 115).
Dermal DC
While pDC are considered to play a vital role in the devel-
opment of psoriatic lesions, DDC are thought to be of major
importance in the more chronic phase of psoriasis. In psoriatic
dermis, CD11c+ DC are increased up to 10 times compared to
non-lesional skin (98, 116, 117). T cells surrounding the DDC
were found to be persistently activated and differentiated toward
a type 1 effector phenotype, both cytotoxic and TH cells (118,
119). Psoriatic lesion-derived DDC were found to be more potent
inducers of spontaneous proliferation of autologous T cells, espe-
cially of the TH1 subtype producing high amounts of IFN-γ
and IL-2, than DDC from HC skin or cDC from peripheral
blood of psoriatic patients (98, 118). Others show that psoriatic
skin-derived DDC not only induce TH1 but also TH17 polar-
ization (120). DDC from psoriatic patients are indeed a potent
source of IL-23 (117, 121–123) and IL-12, although literature
remains in discord on whether or not there is an increase of IL-
12 expression in psoriatic skin compared to normal skin (122,
124, 125).
Dermal dendritic cells in psoriatic skin can be further sub-
divided into three subsets: CD1c+ DC, CD141+ DC, and
CD11c+CD1c−CD141− “inflammatory” DC. Compared to nor-
mal skin, CD1c+ DC numbers are decreased and CD141+ DC
increased in both non-lesional and lesional skin of psoriatic
patients. However, the increase in infDC [up to 30 times compared
to normal skin (120)] is largely responsible for the total increase of
CD11c+ cells in psoriatic lesional skin. Both CD1c+ and CD1c−
DDC populations from psoriatic skin are able to induce T-cell
proliferation and production of IFN-γ and/or IL-17 to the same
extent (120).
Inflammatory DC
“Inflammatory” CD11c+CD1c−CD141− DDC, expressing high
levels of TNF-α and iNOS, specifically accumulate in psori-
atic lesions (126). In analogy with the mouse DC subset, they
have been termed Tip-DC (126). Dermal Tip-DC express some
CD14, CD163, and CD209/DC-SIGN (120) and are assumed to be
monocyte-derived. The pathogenic impact of these DC is thought
to result from the production of pro-inflammatory cytokines.
TNFα induces keratinocytes to express ICAM-1, CXCL8, and also
pro-inflammatory cytokines like IL-1β and IL-6 (102). iNOS in
inflamed tissues catalyzes the production of nitric oxide (NO)
that in inflamed skin can lead to vasodilation of dermal blood ves-
sels in psoriatic skin (102). In addition Tip-DC have been shown
to produce high levels of IL-23, a pro-inflammatory cytokine dri-
ving Th17 polarization and strongly associated with psoriasis (127,
128). Following effective therapy in psoriasis, TNFα, iNOS, and IL-
23 production by Tip-DC is strongly reduced. A (sub-)population
of DC in psoriasis was demonstrated to express 6-SulfoLacNac and
display similarities with peripheral “slanDC” (25). The complete
transcriptional overlap of blood slanDC with CD16+ monocytes,
also suggests a monocyte origin of skin slanDC (13, 23). Like pDC,
dermal slanDC are reactive to self-RNA-LL37 complexes (25) and
their high IL-1β, IL-6, TNFα, IL-12, and IL-23 production results
in TH1/TH17 T-cell programing (25). Because of their phenotypic
signature, it is likely that dermal Tip-DC and slanDC represent
the same infDC population although subpopulations may exist. In
conclusion, accumulating dermal infDC seem to play a key role in
the progression of psoriasis and sustenance of psoriatic lesions by
secreting large amounts of pro-inflammatory mediators including
iNOS, IL-12/IL-23, and TNFα. The latter cytokines, and especially
IL-23, have been proven effective targets for clinical therapy in
psoriasis.
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Langerhans cells
A vital role for LC in psoriasis has not been described thus
far. Compared to normal skin, LC frequency and phenotype are
normal in uninvolved skin of psoriatic patients. However, mobi-
lization of LC toward lymph nodes in response to allergens or
cytokines like TNFα and IL-1β, factors that normally induce
migration of these cells, was largely absent (129). Furthermore,
culture of psoriatic patient-derived monocytes into LC (mLC)
showed migratory capacity similar to those cultured from HC-
derived monocytes, suggesting that there is no intrinsic DC defect
but an underlying altered epidermal microenvironment in psori-
asis patients (130). Such local change may not only influence LC
function, which can be used to distinguish between early-onset
and late-onset psoriasis (131), but perhaps also be the basis for the
development of psoriasis.
Together, there seems to be a pivotal role for DC in the patho-
genesis of psoriasis, not only during the initiation, but also the
sustenance of the disease. However, especially in the non-acute
phase of the disease, it remains difficult to determine what the
exact role is of each DC subset. Moreover, further definition of
these subsets needs to be addressed. While CD11c+CD1c− inflam-
matory DDC were presented as a separate DC subset (71), gene
expression profiling of CD11c+CD1c+ and CD11c+CD1c− DDC
shows that these two populations are closely related (132), sug-
gesting that the inflammatory DDC are perhaps a more activated
form of the CD11c+CD1c+ DDC instead of a distinct subset.
ATOPIC DERMATITIS
Atopic dermatitis, or atopic eczema, like psoriasis, is a common
relapsing inflammatory disease affecting the skin. AD patients
typically present with eczematous patches and plaques, histolog-
ically defined by epidermal intercellular edema (spongiosis) and
prominent dermal cellular infiltration. In AD skin, T-cell numbers
are increased, consisting of mostly TH2 cells in the acute phase
while there is a prominent TH1 aspect in the subacute chronic
phase (133–135). Additionally, like in psoriasis, skin DC numbers
are increased in general, particularly DC expressing CD11c+ and
CD1a+ (136).
Plasmacytoid dendritic cells
In contrast to psoriasis, there seems to be no role for pDC in AD
pathogenesis, since they are virtually absent from AD lesions like in
healthy skin (105). However, peripheral pDC in AD carry the FcεRI
that, when activated induces IL-10 production, while IFN-α pro-
duction is dramatically decreased compared to that by pDC from
HC (137). Together, this may explain the increased susceptibility
of AD patients to viral infections.
Langerhans cells and inflammatory epidermal dendritic cells
Two subsets of FcεRI-bearing DC are most important in AD.
Firstly, LC that show a slightly changed phenotype compared to
steady-state (89). Additionally, infiltrating IDEC are present (89).
Since the majority of these cells are found in the dermis of AD
(136), they are also referred to as myeloid inflammatory dendritic
cells (MIDC).
Both LC and IDEC express high levels of FcεRI (89, 138, 139).
The expression of this FcεRI, in combination with a low expression
of CD32/FCγRII, strongly distinguishes AD patients from patients
with other lesional skin conditions like psoriasis and allergic der-
matitis (140). During the acute phase of AD, in which lesions are
characterized by a TH2 signature, LC may capture antigens via
FcεRI-bound IgE and become activated, leading to secretion of
CCL2/MCP-1 and IL-16, and possibly CXCL8 (141). This induced
attraction of monocytes, eosinophils, and T cells. Additionally,
LC can internalize, process, and present IgE-associated allergens
to T cells, which can take place locally or in skin-draining LN,
resulting in a polarization toward TH2 cells and production of
TH2 cytokines like IL-4, IL-5, IL-13 (141). LC also express high
levels of the receptor for TSLP, a ligand that is secreted in ample
amounts by keratinocytes. Binding TSLP leads to LC maturation,
survival, and secretion of CXCL8, CCL17, CCL22, CCL24, and IL-
15, driving TH2 recruitment. TSLP-induced LC activate TH2 cells,
thereby enhancing the TH2 profile in AD (141, 142).
In the subacute and chronic phase of AD, lesions are more
characterized by a TH1 signature. After migration into the skin
monocytes are thought to differentiate into IDEC, the DC subtype
that seems to be responsible for the chronic maintenance phase of
AD. Phenotypical analysis shows that IDEC are CD1a+, CD1bdim,
CD1cdim, CD11bbright, CD11c+, CD23dim CD32dim, CD36bright,
CD206bright, CD209+, FcεRIbright, IgE+, HLA-DRbright, and neg-
ative for lineage markers (89, 136, 140, 143). After epicutaneous
exposure of AD patients to aero-antigens and food antigens, in
most cases an eczematous reaction ensued, in which case FcεR1-
bearing IDEC were found in the epidermis within 72 h (144). Upon
ligation of FcεRI, these IDEC are able to produce CCL3, IL-1, IL-
16, but also IL-12p70 and IL-18 (141). These latter two cytokines
induce TH1 polarization and production of IFNγ, thus likely con-
tributing to the switch from TH2 to TH1 that leads to the chronic
phase of the disease (133).
Together, also for AD, there seems to be a key role for DC in
the pathogenesis of the disease. In this case, the main role dur-
ing genesis of the disease is assigned to LC, while pDC hardly
play a role. For the chronic phase again there is an infDC type,
but one different from the infDC type prominent in psoriasis.
Interestingly, although skin of AD and psoriasis patients harbors
DC subsets with different characteristics, ex vivo DC subsets from
both disease groups show similar T-cell polarizing ability (145).
In contrast, chemokine expression differs markedly between the
two diseases, showing TH2-associated and some TH1-associated
chemokines in lesional AD skin, while demonstrating mostly
TH1/TH17-associated chemokines in psoriasis (145). These data
would suggest that skin DC do not directly drive T-cell polar-
ization but contribute indirectly by shaping the local chemokine
environment and attracting and further stimulating specific sub-
sets of T cells that are recruited to in the skin. It is important to
realize however that DC responses largely depend on the nature
and extend of the stimulus. While ex vivo triggered DC subsets
may show a high degree of functional plasticity, the tissue context
and local inflammatory environment likely polarize and restrict
their in vivo function.
CONCLUSION
Over the past years, there has been important progress in our
understanding of human DC subsets and their functional roles in
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steady-state conditions. With transcriptional profiling data dis-
tinct subsets of circulating and tissue DC have been defined
and their relationships with monocytes and macrophages have
been further elucidated. In inflammatory conditions, plastic-
ity, and versatility of the DC and monocyte compartments is
revealed with local signals driving their differentiation and func-
tion. The challenge ahead is to define the contributions of DC
subsets in these (pathogenic) inflammatory conditions and its
resolution.
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